Robustelli della Cuna G, Paoletti P, Bernardo G, Knerich R, Butti G, Cuzzoni Q
Neurosurgery. 1982 Sep;11(3):408-11. doi: 10.1227/00006123-198209000-00012.
Two nitrosourea compounds--1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU)--have been used in the treatment of primary and metastatic brain tumors after operation and/or radiotherapy. Hematological and nonhematological toxicity were recorded in 272 patients treated between May 1973 and June 1978. BCNU was given to 135 patients (80 mg/m2 i.v. daily for 3 days) and CCNU was given to 137 patients (130 mg/m2 orally, single dose) every 8 weeks until progression of the primary disease process or for a total of 12 cycles. Radiation therapy (5500 +/- 500 rads in 6 to 7 weeks) was carried out after the first course of chemotherapy. BCNU and CCNU induced the same hematological and clinical toxicity. The bone marrow toxicity seemed to be dose-related, delayed, and cumulative. One case of acute nonlymphoblastic leukemia arising 2 months after the end of CCNU therapy is reported.
两种亚硝基脲化合物——1,3-双（2-氯乙基）-1-亚硝基脲（卡莫司汀，BCNU）和1-（2-氯乙基）-3-环己基-1-亚硝基脲（洛莫司汀，CCNU）——已被用于治疗原发性和转移性脑肿瘤的手术和/或放疗后患者。记录了1973年5月至1978年6月期间接受治疗的272例患者的血液学和非血液学毒性。135例患者接受了BCNU治疗（80mg/m²静脉注射，每日1次，共3天），137例患者接受了CCNU治疗（130mg/m²口服，单次剂量），每8周1次，直至原发性疾病进展或总共进行12个周期。在第一个化疗疗程后进行放射治疗（6至7周内5500±500拉德）。BCNU和CCNU引起相同的血液学和临床毒性。骨髓毒性似乎与剂量相关、具有延迟性且会累积。报告了1例在CCNU治疗结束后2个月发生的急性非淋巴细胞白血病病例。
